Pharmaceutical composition for treating hyperproliferative skin disease and preparation of pharmaceutical composition

A technology for epidermal hyperproliferation and disease, which is applied in the field of pharmacy, can solve the problems of non-persistence and protein kinase signal transduction system defects, etc., and achieves the effects of simple preparation process, uniform drug release and convenient operation.

Active Publication Date: 2014-06-18
XIAN LIBANG PHARMA
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

4. Cyclic adenosine monophosphate (cAMP)-dependent protein kinase (PKA) deficiency on the red blood cell membrane of peripheral blood, cAMP may be a regulator of cell growth and differentiation, cAMP-dependent PKA deficiency in patients with psoriasis, expressed in fibroblasts and red blood cells On the membrane, suggesting a defect in the cAMP-dependent protein kinase signaling system in psoriasis
Its side effects are mild and moderate skin irritation, such as itching, burning sensation, erythema, desquamation, and dryness. These reactions are related to the dosage and dosage form of the drug. They are not durable and can be tolerated. Long-term and large-scale administration can cause teratogenicity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating hyperproliferative skin disease and preparation of pharmaceutical composition
  • Pharmaceutical composition for treating hyperproliferative skin disease and preparation of pharmaceutical composition
  • Pharmaceutical composition for treating hyperproliferative skin disease and preparation of pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0064] Embodiment 1: Contain the emulsifiable paste of 0.001% calcipotriol

[0065] prescription:

[0066]

[0067] method:

[0068] Heat 6g of stearic acid and 3.5g of glyceryl stearate in a water bath until melted, add 0.001g of calcipotriol, 0.1g of tazarotene, 0.1g of betamethasone dipropionate and 0.1g of vitamin E, and stir to dissolve evenly . In addition, heat 70g of PEG-4000 and 10g of PEG-400 in a water bath to 65°C, add 1g of steareth-20, 5g of propylene glycol and 0.1g of ethylparaben, stir evenly, slowly add to the oil phase, stir until the emulsification is complete, add distilled water to 100g, let cool.

Embodiment 2

[0069] Embodiment 2: the cream containing 0.005% calcipotriol

[0070] prescription:

[0071]

[0072] method:

[0073] Heat 6g of stearic acid and 3.5g of glyceryl stearate in a water bath until melted, add 0.005g of calcipotriol, 0.1g of tazarotene, 0.1g of betamethasone dipropionate and 0.1g of vitamin E, and stir to dissolve evenly . In addition, heat 70g of PEG-4000 and 10g of PEG-400 in a water bath to 65°C, add 1g of steareth-20, 5g of propylene glycol and 0.1g of ethylparaben, stir evenly, slowly add to the oil phase, stir until the emulsification is complete, add distilled water to 100g, let cool.

Embodiment 3

[0074] Embodiment 3: Contain the emulsifiable paste of 0.01% calcipotriol

[0075] prescription:

[0076]

[0077] method:

[0078] Heat 6g of stearic acid and 3.5g of glyceryl stearate in a water bath until melted, add 0.01g of calcipotriol, 0.1g of tazarotene, 0.1g of betamethasone dipropionate and 0.1g of vitamin E, and stir to dissolve evenly . In addition, heat 70g of PEG-4000 and 10g of PEG-400 in a water bath to 65°C, add 1g of steareth-20, 5g of propylene glycol and 0.1g of ethylparaben, stir evenly, slowly add to the oil phase, stir until the emulsification is complete, add distilled water to 100g, let cool.

[0079] Part II: The dosage range of tazarotene in ointment

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of pharmacy and particularly relates to a pharmaceutical composition for treating hyperproliferative skin disease and a preparation of the pharmaceutical composition. The pharmaceutical composition comprises the following components by weight percent: 0.001-0.01% (W / W) of calcipotriene, 0.05-2% (W / W) of tazarotene and 0.05-2% (W / W) of adrenocortical hormone.

Description

technical field [0001] The invention belongs to the field of pharmacy, and relates to a pharmaceutical composition and a preparation thereof for treating epidermal hyperproliferative diseases. Background technique [0002] Epidermal hyperproliferative diseases refer to a group of diseases and disorders characterized by higher than normal levels of epidermal cell proliferation and often also by abnormal differentiation. Psoriasis is a typical epidermal hyperproliferative disease. It is a chronic inflammatory skin disease characterized by epidermal KC hyperproliferation and granulocyte infiltration. The severity of symptoms varies from small local plaques to the whole body. Clinically, it is divided into four types: vulgar, pustular, arthropathic and erythrodermic, among which the common type is the most common type in clinical practice. The disease affects 2% to 3% of the total population, and is one of the most common autoimmune diseases in the world. It can occur at any ag...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/00A61K31/593A61K31/4436A61K9/06A61P17/00A61P17/06
Inventor 王汝涛陈涛陈云
Owner XIAN LIBANG PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap